Scientists launch Long-Term study to unravel mysterious immune condition
NCT ID NCT00867269
First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 10 times
Summary
This study follows 950 people with idiopathic CD4+ lymphocytopenia (ICL), a rare condition where low CD4+ white blood cells raise infection risk. Researchers will track participants for up to 10 years, collecting medical history, blood samples, and infection data. The goal is to understand how ICL progresses and what causes it, without testing any new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could reveal genetic or immune factors behind ICL, pointing toward future treatments.
- What could go wrong
- This is an observational study, not testing a treatment. It may not lead to direct therapies, and results depend on long-term follow-up.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRYPTOCOCCAL MENINGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a shorter drug course beat a longer one for a deadly fungal infection?
- Can a blister beetle extract banish common warts? phase 3 trial investigates
- Rare disease drug shows promise in reducing infections
- Can a cancer drug wake up immune cells to beat HIV-Related infections?
- Could a single shot stop deadly meningitis in HIV patients?
- Could a common steroid prevent a deadly complication in AIDS patients?